TZYY-CHOOU C WU

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer
    T C Wu
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Eur J Immunol 37:310-4. 2007
  2. pmc The role of vascular cell adhesion molecule-1 in tumor immune evasion
    T C Wu
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 67:6003-6. 2007
  3. pmc Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
    Archana Monie
    Departments of Pathology
    Biologics 2:97-105. 2008
  4. pmc Efficient delivery of DNA vaccines using human papillomavirus pseudovirions
    S Peng
    Department of Pathology, School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 17:1453-64. 2010
  5. pmc Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA
    T H Kang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 17:531-40. 2010
  6. pmc Prospects for a novel ultrashort pulsed laser technology for pathogen inactivation
    Shaw Wei D Tsen
    Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Biomed Sci 19:62. 2012
  7. pmc One step closer to an experimental infection system for Hepatitis B Virus? --- the identification of sodium taurocholate cotransporting peptide as a viral receptor
    Pei Jer Chen
    Hepatitis Research Center, National Taiwan University and Hospital, Hsinchu City, Taiwan
    Cell Biosci 3:2. 2013
  8. pmc Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen
    Bianca P Gomez
    Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Cell Biosci 2:36. 2012
  9. pmc Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 18:21. 2011
  10. pmc Femtosecond laser treatment enhances DNA transfection efficiency in vivo
    Shaw Wei D Tsen
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21218, USA
    J Biomed Sci 16:36. 2009

Collaborators

Detail Information

Publications75

  1. ncbi request reprint Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer
    T C Wu
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Eur J Immunol 37:310-4. 2007
    ..Continued exploration of HPV therapeutic DNA vaccines may lead to eventual clinical application...
  2. pmc The role of vascular cell adhesion molecule-1 in tumor immune evasion
    T C Wu
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 67:6003-6. 2007
    ..Renal cell carcinoma (RCC) was identified as one tumor type where VCAM-1 is commonly highly overexpressed. Together, our findings suggest that RCCs might exploit VCAM-1 overexpression for immune escape...
  3. pmc Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
    Archana Monie
    Departments of Pathology
    Biologics 2:97-105. 2008
    ..This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development...
  4. pmc Efficient delivery of DNA vaccines using human papillomavirus pseudovirions
    S Peng
    Department of Pathology, School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 17:1453-64. 2010
    ..Our data suggest that DNA vaccines delivered using HPV pseudovirions represent an efficient delivery system that can potentially affect the field of DNA vaccine delivery...
  5. pmc Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA
    T H Kang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 17:531-40. 2010
    ....
  6. pmc Prospects for a novel ultrashort pulsed laser technology for pathogen inactivation
    Shaw Wei D Tsen
    Department of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Biomed Sci 19:62. 2012
    ....
  7. pmc One step closer to an experimental infection system for Hepatitis B Virus? --- the identification of sodium taurocholate cotransporting peptide as a viral receptor
    Pei Jer Chen
    Hepatitis Research Center, National Taiwan University and Hospital, Hsinchu City, Taiwan
    Cell Biosci 3:2. 2013
    ..Wenhui Li and colleagues raised attention again by publishing a possible receptor for hepatitis B virus in eLife. We will briefly review the significance of this finding and the future prospects of hepatitis B research...
  8. pmc Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen
    Bianca P Gomez
    Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Cell Biosci 2:36. 2012
    ..abstract:..
  9. pmc Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 18:21. 2011
    ..In addition, we determined that inducible nitric oxide synthase (iNOS) plays a role in the immune suppression caused by DMXAA administration before DNA vaccination. Our study has significant implications for future clinical translation...
  10. pmc Femtosecond laser treatment enhances DNA transfection efficiency in vivo
    Shaw Wei D Tsen
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21218, USA
    J Biomed Sci 16:36. 2009
    ..Gene therapy with plasmid DNA is emerging as a promising strategy for the treatment of many diseases. One of the major obstacles to such therapy is the poor transfection efficiency of DNA in vivo...
  11. pmc Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
    Chi Mu Chuang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 17:32. 2010
    ..The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer...
  12. pmc DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Cell Biosci 1:26. 2011
    ..abstract:..
  13. pmc In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Cell Biosci 1:3. 2011
    ..abstract:..
  14. pmc Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
    Chao Yi Wu
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 17:88. 2010
    ..Peptide-based vaccines targeting HPV E6 and/or E7 antigens while safe, will most likely require additional strategies to enhance the vaccine potency...
  15. pmc Control of human mesothelin-expressing tumors by DNA vaccines
    C L Chang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:1189-98. 2007
    ..Our data indicated that vaccination with DNA vaccine targeting Hmeso could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibody-mediated immunity...
  16. ncbi request reprint Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
    Chia Jung Hsieh
    Department of Pathology, The Johns Hopkins University School of Medicine, Richard Ross Research Building, Baltimore, MD 21205, USA
    Vaccine 22:3993-4001. 2004
    ..Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy...
  17. pmc Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice
    S Peng
    Department of Pathology, The Johns Hopkins University School of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 13:67-77. 2006
    ..These results highlight the importance of epitope immunodominance in the evaluation of immune responses in HLA-A2 (AAD) transgenic mice...
  18. pmc Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses
    D Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 15:677-87. 2008
    ....
  19. ncbi request reprint CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination
    W F Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 10:1311-20. 2003
    ....
  20. pmc Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Gene Ther 18:1129-39. 2007
    ....
  21. ncbi request reprint Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe
    Cornelia Trimble
    Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institution, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Vaccine 21:4036-42. 2003
    ..m.) and biojector administrations. Thus, our data suggest that DNA vaccination via gene gun represents the most potent regimen for DNA administration...
  22. pmc Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Immunol 180:7019-27. 2008
    ..Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting...
  23. pmc Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Hum Gene Ther 16:584-93. 2005
    ..Our data indicate that transfection of dendritic cells with BAK/BAX siRNA represents a plausible strategy for enhancing dendritic cell-based vaccine potency...
  24. pmc Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope
    C H Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 12:1180-6. 2005
    ..Our data indicate that a DNA vaccine encoding a SCT can lead to stable enhanced MHC class I presentation of encoded antigenic peptide and may be useful for improving DNA vaccine potency to control tumors or infectious diseases...
  25. ncbi request reprint Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes
    Chien Fu Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 63:2393-8. 2003
    ..Our data suggest that the centrosome may be an important locus for MHC class I antigen processing and that targeting antigen to the centrosome can improve DNA vaccine potency...
  26. pmc Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects
    S Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 15:1156-66. 2008
    ..Thus, our study has significant potential for future clinical translation...
  27. ncbi request reprint Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Immunol 171:2970-6. 2003
    ..Therefore, DNA vaccines that combine strategies to enhance intracellular Ag processing and prolong DC life have potential clinical implications for control of viral infection and neoplasia...
  28. pmc Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice
    D Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 15:1176-83. 2008
    ..The clinical implications of the current study are discussed...
  29. ncbi request reprint Comparison of HPV DNA vaccines employing intracellular targeting strategies
    J W Kim
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 11:1011-8. 2004
    ..Our data suggest that the DNA vaccine linking CRT to E7 (CRT/E7) may be a suitable candidate for human trials for the control of HPV infections and HPV-associated lesions...
  30. pmc RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Hum Gene Ther 19:763-73. 2008
    ..Thus, intradermal administration of DNA encoding shRNA represents a plausible approach to silence genes in vivo and a potentially useful tool to enhance DNA vaccine potency...
  31. pmc Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70
    Chih Long Chang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 67:10047-57. 2007
    ..Thus, the use of Hsp70-secreting ovarian tumor cells represents a potentially effective therapy for the control of lethal ovarian cancer...
  32. pmc Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6
    Shiwen Peng
    Department of Pathology, Johns Hopkins University School of Medicine, Ross 512H, 720 Rutland Ave, Baltimore, MD 21205, USA
    J Virol 78:8468-76. 2004
    ..Thus, our data indicate that E6 aa48-57 contains the immunodominant epitope and that a CRT/E6 DNA vaccine may be useful for control of HPV infection and HPV-associated lesions...
  33. pmc A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects
    S Peng
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gene Ther 13:257-65. 2006
    ....
  34. ncbi request reprint Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion
    Wen Fang Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Hum Gene Ther 13:553-68. 2002
    ..Our results indicated that the VP22 strategy used in the context of SIN replicon particles may facilitate the generation of a highly effective vaccine for widespread immunization...
  35. ncbi request reprint DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Hum Gene Ther 16:26-34. 2005
    ....
  36. ncbi request reprint Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects
    Wen Fang Cheng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Biomed Sci 9:675-87. 2002
    ..These results have important clinical implications for the use of naked DNA vaccines in cancer immunotherapy...
  37. ncbi request reprint Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death
    T W Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 11:336-42. 2004
    ..These results suggest that strategies to delay suicidal DNA-induced cell death using antiapoptotic proteins may greatly enhance the potency of suicidal DNA...
  38. pmc Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen
    Chien Fu Hung
    Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    J Virol 76:2676-82. 2002
    ..These results suggested that the development of vaccines encoding VP22 fused to a target antigen might be a promising strategy for improving DNA vaccine potency...
  39. pmc Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination
    Chih Wen Tseng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:3185-92. 2008
    ....
  40. ncbi request reprint Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Cancer Res 64:400-5. 2004
    ..Our results suggest that DNA vaccines combining strategies that enhance MHC class I and II antigen processing with SPI-6 have potential clinical implications for control of viral infection and neoplasia...
  41. ncbi request reprint Preventative and therapeutic vaccines for cervical cancer
    Richard Roden
    Department of Pathology, The Johns Hopkins Medical Institutions, 512H Ross Building, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Expert Rev Vaccines 2:495-516. 2003
    ..Importantly, recent advances in HPV detection and continued improvements in screening further enhance our opportunities to systematically eradicate HPV-associated malignancy...
  42. pmc Generation and characterization of a preventive and therapeutic HPV DNA vaccine
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Vaccine 26:351-60. 2008
    ..Thus, the hCRTE6E7L2 DNA vaccines are capable of generating potent preventive and therapeutic effects in vaccinated mice. Our data has significant clinical implications...
  43. doi request reprint Towards global prevention of human papillomavirus-induced cancer
    Richard B S Roden
    Department of Pathology, The Johns Hopkins University, Baltimore, MD 21231, USA
    Eur J Immunol 38:323-6. 2008
  44. ncbi request reprint Opportunities to improve the prevention and treatment of cervical cancer
    Richard B S Roden
    Departments of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Curr Mol Med 7:490-503. 2007
    ..Importantly, preventive HPV vaccination does not help with current HPV infection or disease. Here we examine the potential of second-generation preventive HPV vaccines and therapeutic HPV vaccination to address these outstanding issues...
  45. ncbi request reprint A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Biomed Sci 11:493-9. 2004
    ....
  46. ncbi request reprint Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies
    Shiwen Peng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 12:689-700. 2005
    ..Our data indicate that all of the intracellular targeting and intercellular spreading strategies that have been shown to enhance E7 DNA vaccine potency were also able to enhance E6 DNA vaccine potency...
  47. ncbi request reprint Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice
    C F Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:20-9. 2007
    ..Thus, intraperitoneal injection with vaccinia virus may provide a potentially effective strategy for treating advanced-stage ovarian cancers...
  48. ncbi request reprint A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors
    Chien Fu Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Vaccine 25:127-35. 2007
    ....
  49. pmc How will HPV vaccines affect cervical cancer?
    Richard Roden
    Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    Nat Rev Cancer 6:753-63. 2006
    ..Here we examine the ramifications and remaining questions that surround preventive HPV vaccines...
  50. pmc Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects
    Chih Wen Tseng
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 26:4314-9. 2008
    ..Our findings serve as an important foundation for future clinical translation...
  51. pmc Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion
    Ken Yu Lin
    Department of Pathology, Institute of Genetic Medicine, Johns Hopkins Medical Institutions, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 67:1832-41. 2007
    ..These data provide evidence that tumor expression of VCAM-1 represents a new mechanism of immune evasion and has important implications for the development of immunotherapy for human RCC...
  52. pmc DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency
    Chien Fu Hung
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Mol Ther 15:1211-9. 2007
    ..Therefore, this strategy may be expected to have significant potential for clinical translation...
  53. pmc Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells
    C F Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Gene Ther 14:921-9. 2007
    ....
  54. ncbi request reprint Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging
    Daejin Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Hum Gene Ther 18:575-88. 2007
    ....
  55. pmc Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination
    Chih Wen Tseng
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Mol Med (Berl) 86:899-908. 2008
    ..Our data have significant implications for future clinical translation...
  56. ncbi request reprint DNA vaccines for cancer
    David Boyd
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    IDrugs 6:1155-64. 2003
    ..If these trials prove DNA vaccines to be clinically effective, they could lead to the development of a new generation of therapies for the treatment and/or prevention of cancer...
  57. pmc DNA vaccines for cervical cancer: from bench to bedside
    Chien Fu Hung
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Exp Mol Med 39:679-89. 2007
    ..The impressive pre- clinical data generated from our studies have led to several HPV DNA vaccine clinical trials...
  58. ncbi request reprint HPV DNA vaccines
    Michelle Moniz
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Front Biosci 8:d55-68. 2003
    ..Should they fulfill their promise, these DNA vaccines may prevent HPV infection or control HPV-related cervical lesions...
  59. pmc Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Invest 112:109-17. 2003
    ..Thus, coadministration of DNA vaccines with DNA encoding antiapoptotic proteins represents an innovative approach to enhance DNA vaccine potency...
  60. pmc Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency
    Bruce Huang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Vaccine 25:7824-31. 2007
    ..Furthermore, we show that mice treated with SCT-E6 and Bcl-xL DNA generated enhanced anti-tumor effects against E6-expressing tumor cells (TC-1/Luciferase) compared to mice treated with SCT-E6 and mtBcl-xL DNA...
  61. ncbi request reprint Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Cancer Res 65:309-16. 2005
    ....
  62. ncbi request reprint Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity
    Tae Woo Kim
    Department of Pathology, Johns Hopkins Medical Institutions, JHU School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Hum Gene Ther 15:167-77. 2004
    ..Thus, administration of DNA encoding VP22 linked to antigen represents a plausible approach for the development of protective DNA vaccines...
  63. pmc Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus
    Tae Woo Kim
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    J Virol 78:4638-45. 2004
    ..These results show that a DNA vaccine encoding CRT linked to a SARS-CoV antigen is capable of generating strong N-specific humoral and cellular immunity and may potentially be useful for control of infection with SARS-CoV...
  64. ncbi request reprint Vaccination to prevent and treat cervical cancer
    Richard B S Roden
    Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA
    Hum Pathol 35:971-82. 2004
    ..If these preventive and therapeutic HPV vaccines prove successful in patients, as they have in animal models, then oncogenic HPV infection and its associated malignancies may be controllable by vaccination...
  65. pmc Therapeutic human papillomavirus vaccines: current clinical trials and future directions
    Chien Fu Hung
    The Johns Hopkins University School of Medicine, Department of Pathology, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, USA
    Expert Opin Biol Ther 8:421-39. 2008
    ..Therapeutic HPV vaccines can potentially eliminate pre-existing lesions and malignant tumors by generating cellular immunity against HPV-infected cells that express early viral proteins such as E6 and E7...
  66. ncbi request reprint Human papillomavirus vaccines for the prevention and treatment of cervical cancer
    Todd T Tomson
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Curr Opin Investig Drugs 5:1247-61. 2004
    ..If these prophylactic and therapeutic HPV vaccines prove as successful in patients as they have in animal models, HPV vaccines may have a role in the control of HPV infection and HPV-associated disease...
  67. ncbi request reprint Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma
    Kalpana Devaraj
    Department of Pathology, The Johns Hopkins Medical Institutions, 720 Rutland Avenue, Ross Building 512, Baltimore, MD 21205, USA
    Crit Rev Oral Biol Med 14:345-62. 2003
    ..Should they fulfill their promise, these vaccines may prevent HPV infection or control its potentially life-threatening consequences in humans...
  68. ncbi request reprint Vaccines against human papillomavirus
    Yen Yu Lin
    Department of Pathology, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, Maryland 21287, USA
    Front Biosci 12:246-64. 2007
    ..If these prophylactic and therapeutic HPV vaccines prove as successful in patients as they have in animal models, vaccination may provide for control and eventually eradication of oncogenic HPV infection and HPV-related cancers...
  69. ncbi request reprint Control of cancers by combining antiangiogenesis and cancer immunotherapy
    Michelle Moniz
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA
    Drugs Today (Barc) 41:471-94. 2005
    ..In addition, we will discuss the feasibility of combining both mechanisms to generate a more powerful strategy for cancer therapy...
  70. ncbi request reprint Focus on endometrial and cervical cancer
    Lora Hedrick Ellenson
    Department of Pathology, The Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Cell 5:533-8. 2004
  71. ncbi request reprint Prospects of RNA interference therapy for cancer
    S I Pai
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Gene Ther 13:464-77. 2006
    ..Significant progress has already been made in addressing some of these issues, and it is foreseen that early phase clinical trials will be initiated in the very near future...
  72. ncbi request reprint Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma
    M Jim Yen
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:827-31. 2006
    ..In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma...
  73. ncbi request reprint Immunotherapeutic strategies employing RNA interference technology for the control of cancers
    Chih Ping Mao
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Biomed Sci 14:15-29. 2007
    ....
  74. ncbi request reprint Preventive and therapeutic HPV vaccines
    Archana Monie
    The Johns Hopkins Medical Institutions, Department of Pathology, 1550 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Investig Drugs 8:1038-50. 2007
    ..Thus, the future of HPV vaccination needs to focus on the development of a new generation of preventive and therapeutic vaccines that are capable of protecting against most cervical cancers...
  75. pmc Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency
    Chih Ping Mao
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    J Virol 84:2331-9. 2010
    ..Thus, the incorporation of FMGs into DNA vaccines holds promise for the successful control of viral infections and cancers in the clinic...

Research Grants18

  1. ENHANCEMENT OF HPV16 E6 & E7-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2001
    ..5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors. ..
  2. PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT
    T C Wu; Fiscal Year: 2002
    ..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
  3. SPORE in Cervical Cancer
    T C Wu; Fiscal Year: 2006
    ..C. Wu, M.D., Ph.D. and Fredrick Montz, M.D.) to facilitate career development of individuals with an interest in translational cervical cancer research. ..
  4. PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT
    T C Wu; Fiscal Year: 2003
    ..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
  5. ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2007
    ..abstract_text> ..
  6. ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2005
    ..abstract_text> ..
  7. ENHANCEMENT OF HPV16 E6 & E7-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2000
    ..5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors. ..
  8. PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT
    T C Wu; Fiscal Year: 2000
    ..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
  9. ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2009
    ..abstract_text> ..
  10. Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)
    T C Wu; Fiscal Year: 2007
    ..The successful implementation of the proposed studies will result in an improved poxvirus DNA vaccine potentially suitable for clinical development. ..
  11. PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT
    T C Wu; Fiscal Year: 2001
    ..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
  12. ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 2006
    ..abstract_text> ..
  13. ENHANCEMENT OF HPV16 E6 & E7-SPECIFIC ANTITUMOR IMMUNITY
    T C Wu; Fiscal Year: 1999
    ..5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors. ..